'Chronic heart failure' diaporamas de présentation

Introduction

Introduction. Clare Kahn, Ph.D. Vice President, US Regulatory Affairs Cardiovascular, Urogenital & Metabolic Products, GlaxoSmithKline. Carvedilol. Pharmacological Properties Nonselective b -adrenergic receptor antagonist ? 1 -adrenergic receptor antagonist. Mild. Moderate. Severe.

1.76k views • 130 slides

Congestive Heart Failure : What your patients need to know.

1.05k views • 75 slides

Sudden Cardiac Arrest: Increasing Survival

Sudden Cardiac Arrest: Increasing Survival. Cynthia M. Tracy, M.D. George Washington University Medical Center. Speaker has no relationships with any proprietary entity producing health care goods or services consumed by or used on patients. Objectives.

934 views • 64 slides

What do they say??

744 views • 49 slides

Four Points: Fatigue

425 views • 42 slides

DRUGS IN HEART FAILURE

DRUGS IN HEART FAILURE. Mari Fotherby & Emma Clingan Heart Failure Specialist Nurses Gloucestershire Heart Failure Service. Introduction. Drug management aims to provide symptomatic relief for the patient while also preventing further deterioration in cardiac function

779 views • 41 slides

Comments on JNC 7: including N.O.D.*

563 views • 39 slides

Coronary Artery Anomalies

Coronary Artery Anomalies. Seoul National University Hospital Department of Thoracic & Cardiovascular Surgery. Coronary Artery Anomalies. Incidence : 1-2% of the population including minor (major anomalies<1% of CHD)

3.02k views • 37 slides

COPD and heart failure

1.63k views • 34 slides

483 views • 30 slides

Journal Club

Journal Club. Raj Chahal. A Shift Towards Rate Control. Tuesday, 14 December 2010. Background. Heart failure has a significant morbidity and mortality burden on the UK. Prevelance of around 900000 in the UK.

1.33k views • 30 slides

Healthcare Economics: Improving Clinical and Economic Outcomes through SJM Technology

Healthcare Economics: Improving Clinical and Economic Outcomes through SJM Technology. HHS Has Taken Aim At Heart Failure Readmissions 1. HF is #1 Medicare expenditure for preventable readmissions

429 views • 28 slides

Chronic Fatigue Syndrome

1.07k views • 28 slides

B&H H&S Network

B&H H&S Network. Network Conference 2010 Heart failure New developments and building new services David Hackett Cardiac Clinical Lead 15 Jul 2010. Heart failure. National Heart Failure audit 2008-09. Average length of stay = 12.7 days. Heart failure. Commissioning.

277 views • 24 slides

Effects of pentoxyfylline in patients with idiopathic dilated cardiomyopathy: a meta-analysis

304 views • 20 slides

Heart Failure (CHF)

354 views • 20 slides

Clinical Trial Commentary

Clinical Trial Commentary. OPTIME CHF and PRAISE II: Recent heart failure trials. Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and Vascular Biology at the Cleveland Clinic Dr Robert Califf Professor of Cardiology

428 views • 19 slides

Troponisms, necrosettes, enzyme leaks, enzyme bumps, infarctlets, minor myocardial damage

342 views • 15 slides

The Studies of Oral Enoximone Therapy in Advanced Heart Failure

ESSENTIAL. The Studies of Oral Enoximone Therapy in Advanced Heart Failure. Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Marco Metra. ESSENTIAL.

237 views • 6 slides

Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency

Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency. Heyder Omran, Giso von der Recke, Harald Schmidt, Christoph Hammerstingl Department of Cardiology, St. Marien- Hospital, Bonn, Germany . Background:

193 views • 1 slides